Gubra A/S (GUBRA) - Total Liabilities
Based on the latest financial reports, Gubra A/S (GUBRA) has total liabilities worth Dkr173.94 Million DKK (≈ $27.21 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Gubra A/S (GUBRA) equity growth momentum to track the company's year-over-year net asset growth rate.
Gubra A/S - Total Liabilities Trend (2019–2025)
This chart illustrates how Gubra A/S's total liabilities have evolved over time, based on quarterly financial data. See GUBRA free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Gubra A/S Competitors by Total Liabilities
The table below lists competitors of Gubra A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hanma Technology Group Co Ltd
SHG:600375
|
China | CN¥4.94 Billion |
|
Equitas Small Finance Bank Limited
NSE:EQUITASBNK
|
India | Rs-60.73 Billion |
|
Beijing CTJ Information Technology Co. Ltd.
SHE:301153
|
China | CN¥477.69 Million |
|
Sedlmayr Grund und Immobilien AG
F:SPB
|
Germany | €980.61 Million |
|
Fiyta Holdings Ltd
SHE:000026
|
China | CN¥368.20 Million |
|
Hangzhou Sunrise Technology Co Ltd
SHE:300360
|
China | CN¥719.08 Million |
|
Aerosun Corp
SHG:600501
|
China | CN¥2.60 Billion |
|
Dalian Insulator Group Co Ltd
SHE:002606
|
China | CN¥1.38 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Gubra A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GUBRA company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gubra A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gubra A/S (2019–2025)
The table below shows the annual total liabilities of Gubra A/S from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Dkr173.94 Million ≈ $27.21 Million |
+7.43% |
| 2024-12-31 | Dkr161.91 Million ≈ $25.33 Million |
+11.19% |
| 2023-12-31 | Dkr145.62 Million ≈ $22.78 Million |
-5.87% |
| 2022-12-31 | Dkr154.69 Million ≈ $24.20 Million |
+2.68% |
| 2021-12-31 | Dkr150.66 Million ≈ $23.57 Million |
+30.82% |
| 2020-12-31 | Dkr115.17 Million ≈ $18.02 Million |
+8.28% |
| 2019-12-31 | Dkr106.36 Million ≈ $16.64 Million |
-- |
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for th… Read more